# Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

> **NCT04508309** · PHASE3 · COMPLETED · sponsor: **PATH** · enrollment: 1025 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** Cecolin®
- **BIOLOGICAL:** Gardasil®

## Key facts

- **NCT ID:** NCT04508309
- **Lead sponsor:** PATH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2023-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 1025 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508309, "Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04508309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*